Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-13
DOI
10.1038/srep29717
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
- (2016) Yongxia Zhu et al. Scientific Reports
- DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization
- (2015) Miroslav Brecik et al. ACS Chemical Biology
- Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives
- (2015) Cui-Ting Peng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Related articles
- (2015) EXPERT OPINION ON PHARMACOTHERAPY
- Bedaquiline and delamanid in tuberculosis
- (2015) Susanna Esposito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Timing is everything for compassionate use of delamanid
- (2015) Clifton E Barry NATURE MEDICINE
- Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis
- (2015) Guido V. Bloemberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery
- (2014) Elizabeth M. Kigondu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Delamanid: First Global Approval
- (2014) Nicola J. Ryan et al. DRUGS
- Towards a new combination therapy for tuberculosis with next generation benzothiazinones
- (2014) V. Makarov et al. EMBO Molecular Medicine
- SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development
- (2014) Giovanna Poce et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity
- (2014) Maruti Naik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Pyrazolopyridones as a Novel Class of Noncovalent DprE1 Inhibitor with Potent Anti-Mycobacterial Activity
- (2014) Manoranjan Panda et al. JOURNAL OF MEDICINAL CHEMISTRY
- The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
- (2013) Giovanna Riccardi et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Synthesis and structure–activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents
- (2013) Chao Gao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo
- (2013) Pravin S. Shirude et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
- (2013) Kevin Pethe et al. NATURE MEDICINE
- Approval of Novel TB Drug Celebrated--With Restraint
- (2013) J. Cohen SCIENCE
- Indoleamides are active against drug-resistant Mycobacterium tuberculosis
- (2013) Shichun Lun et al. Nature Communications
- Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening
- (2012) Sarah A. Stanley et al. ACS Chemical Biology
- In VitroCombination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis
- (2012) Benoit Lechartier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis
- (2012) F. A. Sirgel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
- (2012) Christian Lienhardt et al. JOURNAL OF INFECTIOUS DISEASES
- Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design
- (2012) Tomislav Karoli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Confronting Multidrug-Resistant Tuberculosis
- (2012) Richard E. Chaisson et al. NEW ENGLAND JOURNAL OF MEDICINE
- National Survey of Drug-Resistant Tuberculosis in China
- (2012) Yanlin Zhao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tuberculosis, Drug Resistance, and the History of Modern Medicine
- (2012) Salmaan Keshavjee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors
- (2012) S. M. Batt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
- (2012) Scott G. Franzblau et al. TUBERCULOSIS
- Design, Synthesis, and Evaluation of Thiol-Activated Sources of Sulfur Dioxide (SO2) as Antimycobacterial Agents
- (2011) Satish R. Malwal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure–Activity Relationships for Amide-, Carbamate-, And Urea-Linked Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
- (2011) Adrian Blaser et al. JOURNAL OF MEDICINAL CHEMISTRY
- Decaprenylphosphoryl-β-D-Ribose 2′-Epimerase, the Target of Benzothiazinones and Dinitrobenzamides, Is an Essential Enzyme in Mycobacterium smegmatis
- (2011) Paul K. Crellin et al. PLoS One
- Decaprenylphosphoryl-β-D-Ribose 2-Epimerase from Mycobacterium tuberculosis is a Magic Drug Target
- (2010) G. Manina et al. CURRENT MEDICINAL CHEMISTRY
- Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
- (2009) V. Makarov et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started